News

Hospira relaunches chemotherapy drug

BY Alaric DeArment

LAKE FOREST, Ill. — Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.

The company, which specializes in generic injectables, announced the relaunch of oxaliplatin, a version of Sanofi’s Eloxatin.

Hospira originally launched oxaliplatin in August 2009 after a court ruled in its favor in a patent-infringement suit filed by Sanofi. Sanofi and Hospira later settled the suit in 2010, requiring Hospira to suspend sales of the drug in June 2010, but allowing it to relaunch ahead of the expiration of Sanofi’s patent. The patents on Eloxatin expire between January 2013 and February 2016, according to Food and Drug Administration records.

The Lake Forest, Ill.-based company said the drug had sales of $1.5 billion last year, while IMS Health estimated sales of $1.7 billion for the 12-month period ended in June. Hospira’s launch came the same day as Sagent Pharmaceuticals’ launch of its own generic version of the drug.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Bristol-Myers Squibb, AstraZeneca expand diabetes deal

BY Alaric DeArment

PRINCETON, N.J. — AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter’s acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.

The payment was made as part of the expansion of a deal between the drug manufacturers made in 2007 to develop diabetes drugs. Bristol announced Wednesday that it had completed its acquisition of Amylin, making the San Diego-based drug maker a wholly owned subsidiary.

AstraZeneca also said that pending regulatory approval, it would exercise certain rights over Amylin’s portfolio that it was granted as part of the deal with Bristol, paying Bristol $135 million once it is cleared to do so.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Bartell Drugs to move headquarters

BY Alaric DeArment

SEATTLE — Bartell Drugs is moving its headquarters, the Seattle-based retail pharmacy chain said Thursday.

Bartell’s, which operates 58 stores in and around Washington state’s largest city, said it would move its headquarters to the West Seattle Corporate Center in October. Its present headquarters is in Georgetown, a neighborhood south of downtown Seattle. The new, 32,000-sq.-ft. headquarters was built in 1991 as the headquarters for Services Group of America.

"We’re excited about the move and the built-in advantages it will provide for nearly 100 employees and visiting vendors," vice chairman and treasurer Jean Bartell Barber said, citing fiber-optic capabilities, convenient parking, easy access to major arterials and mass transit, and nearby amenities.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?